Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
AHA: Boehringer plans 2027 survodutide submission after CV win
Boehringer is gearing up to take survodutide to regulators next year after the obesity drug proved its cardiovascular credentials in its latest study.
James Waldron
Nov 9, 2026 9:45am
Fierce Pharma
AZ’s reported $10B offer for Rhythm fuels talks of a bidding war
Nov 5, 2026 9:36am
Rhythm drums up LG obesity license to as much as $855M
Nov 3, 2026 9:32am
Fierce Healthcare
Oura expands clinical research with obesity-treatment study
Oct 29, 2026 8:00am
Why Corxel picked SPAC route to take obesity biotech public
Oct 27, 2026 6:00am
Biomea posts data to pitch oral GLP-1 to potential partners
Oct 14, 2026 9:23am